FDA Approves Ilumya for Active Psoriatic Arthritis

FDA approves expanded Ilumya indication

Sun Pharmaceutical Industries announced on October 30, 2026, that the U.S. Food and Drug Administration approved a supplemental Biologics License Application for Ilumya, according to Securities. The approval covers treatment of adults with active psoriatic arthritis.

Dealroom.co also reported on October 30 that Sun Pharma won U.S. FDA approval for Ilumya in psoriatic arthritis. Securities identified Ilumya as tildrakizumab-asmn.

The reported FDA action adds active psoriatic arthritis to the treatment scope for Ilumya described in Sun Pharma’s announcement. Securities reported that Ilumya had previously been indicated for moderate-to-severe plaque psoriasis.

Reported product and regulatory details

Securities described Ilumya as an IL-23 inhibitor and said the FDA approved the supplemental Biologics License Application for treatment of adults with active psoriatic arthritis. The report characterized the decision as an expansion beyond the medicine’s plaque psoriasis indication.

For pharmaceutical and biotech sales professionals, the approval is a regulatory update involving an existing Sun Pharma product and a new reported treatment population: adults with active psoriatic arthritis. The available reports identify the action as an FDA approval rather than a separate product launch.

Key details from the reports

• Company: Sun Pharmaceutical Industries
• Product: Ilumya
• Product name reported by Securities: tildrakizumab-asmn
• Regulatory action: FDA approval of a supplemental Biologics License Application
• Approved population: Adults with active psoriatic arthritis
• Previously reported indication: Moderate-to-severe plaque psoriasis
• Product class reported by Securities: IL-23 inhibitor

Publisher coverage

Dealroom.co reported that Sun Pharma won U.S. FDA approval for Ilumya in psoriatic arthritis. Securities reported that the approval applies to adults with active psoriatic arthritis and expands Ilumya beyond moderate-to-severe plaque psoriasis.

The reports were published October 30, 2026, following Sun Pharma’s announcement on that date, according to Securities.